Abstract library

744 results for "sequential therapy".
#628 Sequential Chemo-Radiation Therapy for Locally Advanced Neuroendocrine Carcinoma of Head and Neck
Introduction: Neuroendocrine carcinomas (NECs) of the head and neck are considered an infrequent clinico-pathological entity. Combined modality treatment represents an established therapeutic option for poorly differentiated forms where distant metastasis is a common pattern of failure.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Young Mi Seol
Authors:
#1899 Sequence of Therapy and Survival among Advanced Pancreatic Neuroendocrine Tumors (pNETs)
Introduction: Therapy for advanced pNETs involves surgery (SG) and non-SG options, including liver ablation (ABL), systemic therapy (ST), somatostatin analogues (SSA). Optimal initial therapy is unknown.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Erica Tsang
Authors:
#1471 Chemotherapy for Stage IV Sporadic Pancreatic Neuroendocrine Tumors (pNET): Are Partial Responses to Post-first Line Chemotherapy Predictable by Response/Type of First Line Chemotherapy?
Introduction: Three types of chemotherapy are recommended for stage IV pancreatic neuroendocrine tumors (pNETs): streptozocin (STZ)-, dacarbazine (DCZ)- and oxaliplatin (OX)-based. Whether cross resistance exists is unknown.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Medical Doctor Vincenzo Marotta
Authors:
#817 Surgery after Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Introduction: There are a few case reports on surgery after peptide receptor radionuclide therapy (PRRT).
Conference: 11th Annual ENETS Conference (2014)
Category: Surgical treatment
Presenting Author: Emilio Bertani
Authors:
#27 Combined treatment of rapidly progressing neuroendocrine tumors by transcatheter arterial chemoembolisation of the liver and peptide-receptor radiotherapy is save and effective. Report of thirty consecutive patients
Introduction: Patients with rapidly progressing neuroendocrine tumors presenting with high tumor load and/or severe clinical syndromes are clinically challenging and with limited life expectany. Peptide receptor radiotherapy (PRRT) and transcatheter arterial chemoembolization (TACE) have demonstrated efficacy in the treatment of neuroendocrine tumors. However, there are no reports that both therapies have been applied in combination.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Dieter Hörsch
Authors:
Keywords: PRRT, TACE
#1404 The Proteasome Inhibitor Bortezomib Is a Highly Effective Treatment Option for Gastroenteropancreatic Neuroendocrine Neoplasms and Sensitizes to DNA Damaging Therapy In Vitro
Introduction: Gastroenteropancreatic neuroendocrine neoplasms are fairly rare tumors with very heterogeneous behavior and molecular characteristics. Their generally slow proliferation render them virtually resistant to many DNA damaging therapeutic approaches. Bortezomib has been shown to be effective in GEP-NENs in vitro but has been withdrawn from clinical assessment due to a small phase II study on bortezomib monotherapy in 2004.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Franziska Briest
Authors:
#290 Peptide Receptor Radiotherapy as a Potential Tool of Neoadjuvant Therapy in Patients with Inoperable Neuroendocrine Tumors (NETs)
Introduction: Neoadjuvant treatment is used as pre-surgical therapy in different cancers to decrease tumor size. PRRT can be a useful tool in neoadjuvant treatment of patients with well-differentiated NETs.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Anna Sowa-Staszczak
Authors:
#1496 Sequential Everolimus and Sunitinib Treatment in Pancreatic Metastatic Well-differentiated Neuroendocrine Tumors Resistant to Prior Treatments
Introduction: Alternating treatment with sunitinib and everolimus, has been shown to be efficacious in renal cell carcinoma
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Anna Angelousi
Authors:
#1786 Targeted Therapies (TT) (Sunitinib and Everolimus) for Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET). A Case Series
Introduction: Sunitinib (Sun) and Everolimus (Eve) are effective treatments for advanced GEP-NET. Lack of standard treatment sequencing and potential toxicities may preclude it´s use.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Juan Manuel O'Connor
Authors:
Keywords: TNE, therapy target
#1375 Merkel Cell Carcinoma of the Knee Treated with Somatostatin Analogue and Radiotherapy: A Case Report
Introduction: Merkel cell carcinoma (MCC) is a rare and aggressive primary cutaneous neuroendocrine malignancy. Chemotherapy with cisplatin (CDDP) and etoposide (VP16) is an effective treatment for metastatic MCC.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Ivana Puliafito
Authors: